Ubs Group Ag Chimerix Inc Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

A detailed history of Ubs Group Ag transactions in Chimerix Inc stock. As of the latest transaction made, Ubs Group Ag holds 91,384 shares of CMRX stock, worth $80,417. This represents 0.0% of its overall portfolio holdings.

Number of Shares
91,384
Previous 17,360 426.41%
Holding current value
$80,417
Previous $15,000 460.0%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$0.77 - $1.07 $56,998 - $79,205
74,024 Added 426.41%
91,384 $84,000
Q2 2024

Aug 13, 2024
SELL
$0.87 - $1.05 $9,466 - $11,425
-10,881 Reduced 38.53%
17,360 $15,000
Q1 2024

May 13, 2024
SELL
$0.91 - $1.26 $14,664 - $20,304
-16,115 Reduced 36.33%
28,241 $29,000
Q4 2023

Feb 09, 2024
SELL
$0.9 - $1.06 $70,833 - $83,426
-78,704 Reduced 63.96%
44,356 $42,000
Q3 2023

Nov 09, 2023
SELL
$0.94 - $1.23 $152,462 - $199,498
-162,194 Reduced 56.86%
123,060 $118,000
Q2 2023

Aug 11, 2023
BUY
$1.1 - $1.54 $99,182 - $138,855
90,166 Added 46.22%
285,254 $345,000
Q1 2023

May 12, 2023
SELL
$1.19 - $2.09 $75,794 - $133,118
-63,693 Reduced 24.61%
195,088 $245,000
Q4 2022

Feb 08, 2023
SELL
$1.67 - $2.35 $195,877 - $275,636
-117,292 Reduced 31.19%
258,781 $481,000
Q3 2022

Nov 10, 2022
BUY
$1.81 - $2.76 $557,271 - $849,762
307,885 Added 451.52%
376,073 $725,000
Q2 2022

Aug 10, 2022
SELL
$1.34 - $5.34 $261,439 - $1.04 Million
-195,104 Reduced 74.1%
68,188 $142,000
Q1 2022

May 16, 2022
BUY
$4.58 - $6.8 $125,867 - $186,877
27,482 Added 11.65%
263,292 $1.21 Million
Q4 2021

Feb 14, 2022
BUY
$5.23 - $7.18 $475,914 - $653,358
90,997 Added 62.84%
235,810 $1.52 Million
Q3 2021

Nov 15, 2021
SELL
$5.94 - $8.75 $355,010 - $522,952
-59,766 Reduced 29.21%
144,813 $896,000
Q2 2021

Aug 13, 2021
SELL
$7.54 - $9.79 $713,992 - $927,054
-94,694 Reduced 31.64%
204,579 $1.64 Million
Q1 2021

May 12, 2021
BUY
$4.76 - $11.25 $1.38 Million - $3.26 Million
289,412 Added 2934.92%
299,273 $2.89 Million
Q4 2020

Feb 11, 2021
BUY
$2.43 - $5.42 $22,562 - $50,324
9,285 Added 1611.98%
9,861 $48,000
Q3 2020

Nov 12, 2020
SELL
$2.3 - $3.72 $41,899 - $67,767
-18,217 Reduced 96.94%
576 $1,000
Q2 2020

Jul 31, 2020
SELL
$1.33 - $3.63 $612,192 - $1.67 Million
-460,295 Reduced 96.08%
18,793 $58,000
Q1 2020

May 01, 2020
SELL
$1.27 - $2.33 $135,284 - $248,198
-106,523 Reduced 18.19%
479,088 $690,000
Q4 2019

Feb 14, 2020
BUY
$1.3 - $2.72 $17,982 - $37,625
13,833 Added 2.42%
585,611 $1.19 Million
Q3 2019

Nov 14, 2019
BUY
$1.93 - $4.21 $48,408 - $105,595
25,082 Added 4.59%
571,778 $1.34 Million
Q2 2019

Aug 14, 2019
BUY
$2.05 - $4.32 $1.12 Million - $2.36 Million
546,566 Added 420435.38%
546,696 $2.36 Million
Q1 2019

May 14, 2019
SELL
$1.79 - $3.12 $30,127 - $52,512
-16,831 Reduced 99.23%
130 $0
Q4 2018

Feb 14, 2019
BUY
$2.24 - $3.9 $22,550 - $39,261
10,067 Added 146.03%
16,961 $43,000
Q3 2018

Nov 14, 2018
SELL
$3.58 - $4.9 $4,711 - $6,448
-1,316 Reduced 16.03%
6,894 $27,000
Q2 2018

Aug 14, 2018
BUY
$4.43 - $5.14 $19,554 - $22,687
4,414 Added 116.28%
8,210 $39,000
Q1 2018

May 15, 2018
SELL
$4.65 - $5.9 $7,756 - $9,841
-1,668 Reduced 30.53%
3,796 $20,000
Q4 2017

Feb 14, 2018
BUY
$4.32 - $5.52 $1,909 - $2,439
442 Added 8.8%
5,464 $25,000
Q3 2017

Nov 14, 2017
BUY
$4.35 - $5.25 $408 - $493
94 Added 1.91%
5,022 $26,000
Q2 2017

Aug 14, 2017
BUY
N/A
410 Added 9.07%
4,928 $27,000
Q1 2017

Nov 14, 2017
BUY
N/A
4,518
4,518 $28,000

Others Institutions Holding CMRX

# of Institutions
70
Shares Held
37M
Call Options Held
52.7K
Put Options Held
130K
View Full List

About CHIMERIX INC

CMRX Quotes by TradingView
  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $77.1M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email